"10.1371_journal.pone.0150320","plos one","2016-03-18T00:00:00Z","Yaffa Mizrachi Nebenzahl; Karin Blau; Tatyana Kushnir; Marilou Shagan; Maxim Portnoi; Aviad Cohen; Shalhevet Azriel; Itai Malka; Asad Adawi; Daniel Kafka; Shahar Dotan; Gali Guterman; Shany Troib; Tali Fishilevich; Jonathan M Gershoni; Alex Braiman; Andrea M Mitchell; Timothy J Mitchell; Nurith Porat; Inna Goliand; Vered Chalifa Caspi; Edwin Swiatlo; Michael Tal; Ronald Ellis; Natalie Elia; Ron Dagan","Pediatric Infectious Disease Unit, Soroka University Medical Center, Beer Sheva, Israel; The Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel; The Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel; NasVax Ltd, Ness Ziona, Israel; Department of Cell Research and Immunology, Tel-Aviv University, Tel-Aviv, Israel; Institute of Microbiology and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom; National Institute of Biotechnology in the Negev, Ben-Gurion University of the Negev, Beer Sheva, Israel; Department of Life Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel; Division of Infectious Diseases, University of Mississippi Medical Center, Jackson, MS, United States of America","Conceived and designed the experiments: YMN JMG RE NP NE RD MT. Performed the experiments: KB TK MS MP AC SA IM AA DK SD GG ST TF AB IG ES. Analyzed the data: YMN MS TK VCC. Contributed reagents/materials/analysis tools: AMM TJM. Wrote the paper: YMN TK TJM.","This study was partly funded by BG Negev Technologies. The study and part of the authors were partially funded by a commercial company (Nasvax Ltd./Protea Vaccine Technologies Ltd.) through the BGNegev Biotechnologies which is the BGU industrial liaison. Nasvax Ltd./Protea Vaccine Technologies Ltd. is the employer of authors Shahar Dotan, Michael Tal and Ronald Ellis. The PtsA protein discussed in the enclosed manuscript is protected by several pending patents: US 7,504,110; EP 2275128; US 8,691,243 B2. The protein vaccine is at an early stage of preclinical studies. There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2016","03","Yaffa Mizrachi Nebenzahl","YMN",26,TRUE,7,16,4,3,TRUE,TRUE,FALSE,0,NA,FALSE
